The Point-of-Care Peritoneal Dialysis System Early Evaluation Study (POC-PDEE): A pilot proof-of-principal study of the Ellen Medical Devices Point-of-Care affordable peritoneal dialysis system
- PMID: 38179591
- DOI: 10.1177/08968608231209850
The Point-of-Care Peritoneal Dialysis System Early Evaluation Study (POC-PDEE): A pilot proof-of-principal study of the Ellen Medical Devices Point-of-Care affordable peritoneal dialysis system
Abstract
The global unmet need for kidney replacement therapy means that millions of people die every year as they cannot afford treatment. Peritoneal dialysis (PD) offers comparable survival to haemodialysis and is often more affordable, but one barrier to increasing access is that conventional manufacturing and distribution of PD fluid is costly. Here we report the results from a pilot proof-of-principal study demonstrating for the first time that the Ellen Medical Devices Point-of-Care system can be used by patients to produce sterile PD fluid at the point-of-care. With further development, this low-cost system could offer a solution to the many millions of people around the world who currently cannot afford treatment for kidney failure.
Keywords: Low-cost; PD fluid; peritoneal dialysis; point-of-care.
Conflict of interest statement
Declaration of conflicting interestThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: BT, JB, VG, AB, NK and JK are employees of Ellen Medical Devices on secondment from the George Institute for Global Health. BT, VG, VP, MJ, MG and JK are employees or hold appointments at the George Institute for Global Health which is the majority owner of Ellen Medical Devices. These relationships are considered to be synergies rather than conflicts. SD receives research funding from Baxter HealthCare, lecture fees from Baxter and Fresenius Medical Care, Advisory Board Fees from Ellen Medical and is president of EuroPD. MJ is responsible for research projects that have received funding from Amgen, Baxter, CSL, Dimerix, Eli Lilly, Gambro and MSD; has received fees for Advisory, Steering Committee and/or Scientific Presentations from Akebia, Amgen, Astra Zeneca, Baxter, Bayer, Boehringer Ingelheim, Cesas Linx, Chinook, CSL, Janssen, Medscape, MSD, Roche and Vifor; with any consultancy, honoraria or travel support paid to her institution.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical